Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Total Voting Rights

28 Feb 2012 08:00

RNS Number : 2470Y
Angle PLC
28 February 2012
 



For immediate release

28 February 2012

 

ANGLE plc

("ANGLE" or the "Company")

 

Issue of Equity and Total Voting Rights

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that it has now received Advanced Assurance from HMRC of eligibility for EIS and VCT relief in relation to the new ordinary shares of 10 pence each (the "Fundraising Shares") to be issued pursuant to the fundraising announced on 26 January 2012. As a result, the Company has applied for the Fundraising Shares to be admitted to trading on AIM. Admission of the Fundraising Shares to trading on AIM is expected as to 1,187,145 Ordinary shares at 8.00am on 2 March 2012 for the EIS and VCT qualifying investors and as to 528,572 Ordinary shares at 8.00am on 5 March 2012 for the other investors ("Admission").

For the purposes of the Financial Services Authority's Disclosure and Transparency Rules, the Company's total issued share capital following Admission will consist of 37,824,559 Ordinary Shares of 10 pence each, with one voting right per share. There are no shares held in treasury.

The total number of voting rights in the Company will therefore be 37,824,559.

The above figure of 37,824,559 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company, under the Disclosure and Transparency Rules.

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated Adviser)

Andy Roberts (Sales)

 

020 7397 8900

 

 

Buchanan

Mark Court, Sophie Cowles

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

 

020 7653 0030

 

 

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVRPGUCWPUPPUMR
Date   Source Headline
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date
22nd Jan 20207:00 amRNSSuccessful face-to-face meeting with FDA
8th Jan 202012:33 pmRNSNotice of Results
23rd Dec 20199:55 amRNSIssue of Equity
7th Nov 20197:00 amRNSCancer centre shows Parsortix use in melanoma
30th Oct 20192:44 pmRNSResult of AGM
30th Oct 20197:00 amRNSQ-submission to FDA containing headline data
8th Oct 20197:00 amRNSNotice of AGM
4th Oct 20195:54 pmRNSHolding(s) in Company
4th Oct 20197:00 amRNSEuropean patent granted for megakaryocyte analysis
13th Sep 20197:00 amRNSUse of Parsortix in head and neck cancer
10th Sep 20197:00 amRNSResearch with Parsortix in prostate cancer
4th Sep 20197:00 amRNSParsortix for Neuroendocrine Analysis in SCLC
29th Aug 20197:00 amRNSInitiation of Ovarian Cancer Study
31st Jul 20197:00 amRNSPrelim Results for the year ended 30 April 2019
22nd Jul 20197:00 amRNSUse of Parsortix for single cell analysis of CTCs
16th Jul 20199:19 amRNSHolding(s) in Company
12th Jul 201910:22 amRNSResult of General Meeting anf Total Voting Rights
28th Jun 20191:37 pmRNSNotice of Preliminary Results and Webcast
28th Jun 20191:08 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.